Realcan Pharmaceutical Group Co., Ltd. (SHE:002589)
China
· Delayed Price · Currency is CNY 2.980
+0.020 (0.68%)
May 30, 2025, 3:04 PM CST
SHE:002589 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 7,642 | 7,904 | 7,976 | 12,264 | 20,913 | 26,985 | Upgrade
|
| Other Revenue | 62.07 | 62.07 | 57.97 | 47.5 | 146.6 | 248.62 | Upgrade
|
| Revenue | 7,704 | 7,966 | 8,034 | 12,311 | 21,060 | 27,234 | Upgrade
|
| Revenue Growth (YoY) | -3.46% | -0.85% | -34.74% | -41.54% | -22.67% | -22.76% | Upgrade
|
| Cost of Revenue | 6,833 | 7,096 | 7,212 | 10,683 | 17,315 | 22,374 | Upgrade
|
| Gross Profit | 870.86 | 870.74 | 822.06 | 1,628 | 3,745 | 4,860 | Upgrade
|
| Selling, General & Admin | 758.03 | 749.93 | 835.99 | 1,503 | 2,668 | 3,201 | Upgrade
|
| Research & Development | 9.88 | 10.03 | 14.62 | 22.68 | 11.56 | 8.91 | Upgrade
|
| Other Operating Expenses | 39.09 | 36.91 | 45.72 | 52.13 | 93.7 | 104.41 | Upgrade
|
| Operating Expenses | 854.71 | 839.98 | 906.33 | 1,737 | 2,932 | 3,437 | Upgrade
|
| Operating Income | 16.16 | 30.76 | -84.27 | -108.72 | 813.41 | 1,422 | Upgrade
|
| Interest Expense | -201.86 | -193.87 | -303.7 | -407.71 | -554.42 | -613.95 | Upgrade
|
| Interest & Investment Income | 186.84 | 184.11 | 599.53 | 83.97 | 251.17 | 329.82 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.02 | -0.02 | 0 | -0 | 0.01 | -0.76 | Upgrade
|
| Other Non Operating Income (Expenses) | -33.66 | -47.31 | -77.37 | -169.88 | -121.5 | -142.3 | Upgrade
|
| EBT Excluding Unusual Items | -32.54 | -26.33 | 134.19 | -602.33 | 388.68 | 994.9 | Upgrade
|
| Impairment of Goodwill | - | - | -0.02 | -22.94 | -39.67 | -24.23 | Upgrade
|
| Gain (Loss) on Sale of Investments | 29.76 | 30.65 | -261.66 | -1,087 | 82.15 | -87.02 | Upgrade
|
| Gain (Loss) on Sale of Assets | 24.8 | 18.94 | -7.92 | -1 | 3.06 | 3.78 | Upgrade
|
| Asset Writedown | -0.61 | -0.61 | -4.89 | -24.89 | -0.24 | -1.2 | Upgrade
|
| Other Unusual Items | 19.15 | 18.93 | 4.89 | -4.98 | 31.04 | 30.06 | Upgrade
|
| Pretax Income | 40.55 | 41.57 | -135.42 | -1,744 | 465.02 | 916.3 | Upgrade
|
| Income Tax Expense | -1.33 | 0.55 | -167.39 | -4.88 | 83.01 | 290.93 | Upgrade
|
| Earnings From Continuing Operations | 41.88 | 41.02 | 31.97 | -1,739 | 382.01 | 625.37 | Upgrade
|
| Minority Interest in Earnings | -22.26 | -20.4 | -11.65 | -92.17 | -250.83 | -364.07 | Upgrade
|
| Net Income | 19.62 | 20.62 | 20.32 | -1,831 | 131.18 | 261.3 | Upgrade
|
| Net Income to Common | 19.62 | 20.62 | 20.32 | -1,831 | 131.18 | 261.3 | Upgrade
|
| Net Income Growth | 36.97% | 1.50% | - | - | -49.80% | - | Upgrade
|
| Shares Outstanding (Basic) | 1,507 | 1,505 | 1,505 | 1,477 | 1,458 | 1,452 | Upgrade
|
| Shares Outstanding (Diluted) | 1,507 | 1,505 | 1,505 | 1,477 | 1,458 | 1,452 | Upgrade
|
| Shares Change (YoY) | 0.27% | 0.01% | 1.93% | 1.30% | 0.40% | -2.99% | Upgrade
|
| EPS (Basic) | 0.01 | 0.01 | 0.01 | -1.24 | 0.09 | 0.18 | Upgrade
|
| EPS (Diluted) | 0.01 | 0.01 | 0.01 | -1.24 | 0.09 | 0.18 | Upgrade
|
| EPS Growth | 36.61% | 1.48% | - | - | -50.00% | - | Upgrade
|
| Free Cash Flow | 134.38 | 48.92 | -215.92 | 352.11 | -18.13 | -225.19 | Upgrade
|
| Free Cash Flow Per Share | 0.09 | 0.03 | -0.14 | 0.24 | -0.01 | -0.15 | Upgrade
|
| Dividend Per Share | 0.011 | 0.011 | 0.013 | - | 0.009 | 0.018 | Upgrade
|
| Dividend Growth | -15.38% | -15.38% | - | - | -50.00% | - | Upgrade
|
| Gross Margin | 11.30% | 10.93% | 10.23% | 13.23% | 17.78% | 17.84% | Upgrade
|
| Operating Margin | 0.21% | 0.39% | -1.05% | -0.88% | 3.86% | 5.22% | Upgrade
|
| Profit Margin | 0.26% | 0.26% | 0.25% | -14.87% | 0.62% | 0.96% | Upgrade
|
| Free Cash Flow Margin | 1.74% | 0.61% | -2.69% | 2.86% | -0.09% | -0.83% | Upgrade
|
| EBITDA | 164.34 | 192.34 | 130.9 | 165.95 | 1,113 | 1,713 | Upgrade
|
| EBITDA Margin | 2.13% | 2.41% | 1.63% | 1.35% | 5.29% | 6.29% | Upgrade
|
| D&A For EBITDA | 148.19 | 161.59 | 215.17 | 274.67 | 299.78 | 291.41 | Upgrade
|
| EBIT | 16.16 | 30.76 | -84.27 | -108.72 | 813.41 | 1,422 | Upgrade
|
| EBIT Margin | 0.21% | 0.39% | -1.05% | -0.88% | 3.86% | 5.22% | Upgrade
|
| Effective Tax Rate | - | 1.33% | - | - | 17.85% | 31.75% | Upgrade
|
| Revenue as Reported | 7,704 | 7,966 | 8,034 | 12,311 | 21,060 | 27,234 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.